Edition:
United Kingdom

Immunomedics Inc (IMMU.OQ)

IMMU.OQ on NASDAQ Stock Exchange Global Market

16.74USD
7:49pm GMT
Change (% chg)

$0.52 (+3.21%)
Prev Close
$16.22
Open
$16.32
Day's High
$17.03
Day's Low
$16.32
Volume
192,765
Avg. Vol
820,888
52-wk High
$18.93
52-wk Low
$4.73

Select another date:

Thu, Feb 8 2018

BRIEF-Immunomedics Q2 Loss Per Share $0.02

* IMMUNOMEDICS ANNOUNCES SECOND QUARTER FISCAL 2018 RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Immunomedics Announces Agreement With University Of Wisconsin Carbone Cancer Center To Expand Sacituzumab Govitecan Into Prostate Cancer

* IMMUNOMEDICS ANNOUNCES AGREEMENT WITH UNIVERSITY OF WISCONSIN CARBONE CANCER CENTER TO EXPAND SACITUZUMAB GOVITECAN (IMMU-132) INTO PROSTATE CANCER

BRIEF-Immunomedics, Royalty Pharma Announce Royalty Funding And Stock Purchase Agreements Totalling $250 Mln

* IMMUNOMEDICS AND ROYALTY PHARMA ANNOUNCE ROYALTY FUNDING AND STOCK PURCHASE AGREEMENTS TOTALLING $250 MILLION

BRIEF-Immunomedics appoints Michael Pehl president and CEO

* Immunomedics appoints Michael Pehl president and chief executive officer to lead next phase of transformative growth

BRIEF-Immunomedics announces first quarter fiscal results

* Immunomedics announces first quarter fiscal 2018 results and provides corporate update

BRIEF-Immunomedics to exchange about $80 mln of its 4.75 pct Convertible Senior Notes due 2020 for common stock

* Immunomedics announces agreements to exchange approximately $80.0 mln of its 4.75 pct Convertible Senior Notes due 2020 for common stock

BRIEF-Immunomedics presents interim phase 2 results with sacituzumab govitecan (i

* Immunomedics presents interim phase 2 results with sacituzumab govitecan (immu-132) in patients with pretreated metastatic urothelial cancer Source text for Eikon: Further company coverage:

Select another date: